US20220143121A1 - Therapeutic treatment for the coronavirus disease covid-19 - Google Patents

Therapeutic treatment for the coronavirus disease covid-19 Download PDF

Info

Publication number
US20220143121A1
US20220143121A1 US17/602,234 US202117602234A US2022143121A1 US 20220143121 A1 US20220143121 A1 US 20220143121A1 US 202117602234 A US202117602234 A US 202117602234A US 2022143121 A1 US2022143121 A1 US 2022143121A1
Authority
US
United States
Prior art keywords
patient
thyme
disclosed
treatment
coronavirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US17/602,234
Other languages
English (en)
Inventor
Peter Joseph Mollick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US17/602,234 priority Critical patent/US20220143121A1/en
Publication of US20220143121A1 publication Critical patent/US20220143121A1/en
Priority to US18/104,030 priority patent/US11865154B2/en
Priority to US18/388,823 priority patent/US20240075090A1/en
Priority to US18/388,854 priority patent/US20240082336A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Virology (AREA)
  • Nutrition Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Physiology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Molecular Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
US17/602,234 2020-04-02 2021-04-01 Therapeutic treatment for the coronavirus disease covid-19 Abandoned US20220143121A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US17/602,234 US20220143121A1 (en) 2020-04-02 2021-04-01 Therapeutic treatment for the coronavirus disease covid-19
US18/104,030 US11865154B2 (en) 2020-04-02 2023-01-31 Therapeutic treatment for the coronavirus disease COVID-19
US18/388,823 US20240075090A1 (en) 2020-04-02 2023-11-11 Therapeutic treatment for the coronavirus disease covid-19
US18/388,854 US20240082336A1 (en) 2020-04-02 2023-11-12 Therapeutic treatment for the coronavirus disease covid-19

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063100831P 2020-04-02 2020-04-02
US202063102925P 2020-07-08 2020-07-08
PCT/US2021/025298 WO2021202823A1 (fr) 2020-04-02 2021-04-01 Traitement thérapeutique pour la maladie de coronavirus covid-19
US17/602,234 US20220143121A1 (en) 2020-04-02 2021-04-01 Therapeutic treatment for the coronavirus disease covid-19

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/025298 A-371-Of-International WO2021202823A1 (fr) 2020-04-02 2021-04-01 Traitement thérapeutique pour la maladie de coronavirus covid-19

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US18/104,030 Division US11865154B2 (en) 2020-04-02 2023-01-31 Therapeutic treatment for the coronavirus disease COVID-19

Publications (1)

Publication Number Publication Date
US20220143121A1 true US20220143121A1 (en) 2022-05-12

Family

ID=77927462

Family Applications (4)

Application Number Title Priority Date Filing Date
US17/602,234 Abandoned US20220143121A1 (en) 2020-04-02 2021-04-01 Therapeutic treatment for the coronavirus disease covid-19
US18/104,030 Active US11865154B2 (en) 2020-04-02 2023-01-31 Therapeutic treatment for the coronavirus disease COVID-19
US18/388,823 Pending US20240075090A1 (en) 2020-04-02 2023-11-11 Therapeutic treatment for the coronavirus disease covid-19
US18/388,854 Pending US20240082336A1 (en) 2020-04-02 2023-11-12 Therapeutic treatment for the coronavirus disease covid-19

Family Applications After (3)

Application Number Title Priority Date Filing Date
US18/104,030 Active US11865154B2 (en) 2020-04-02 2023-01-31 Therapeutic treatment for the coronavirus disease COVID-19
US18/388,823 Pending US20240075090A1 (en) 2020-04-02 2023-11-11 Therapeutic treatment for the coronavirus disease covid-19
US18/388,854 Pending US20240082336A1 (en) 2020-04-02 2023-11-12 Therapeutic treatment for the coronavirus disease covid-19

Country Status (6)

Country Link
US (4) US20220143121A1 (fr)
EP (1) EP4125981A4 (fr)
AU (1) AU2021246761A1 (fr)
CA (1) CA3179222A1 (fr)
GB (1) GB2595427A (fr)
WO (1) WO2021202823A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD2470F1 (en) * 2002-09-06 2004-06-30 Inst Cercetari Stiintifice Process for production of snack canned chick-pea
CN106179143A (zh) * 2016-08-25 2016-12-07 上海应用技术学院 一种薰衣草香精淀粉胶囊及其制备方法
US20190298787A1 (en) * 2018-04-02 2019-10-03 Imam Abdulrahman Bin Faisal University Antimicrobial extracts of boswellia and thyme

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040071757A1 (en) * 2001-11-20 2004-04-15 David Rolf Inhalation antiviral patch
WO2005030172A1 (fr) * 2003-09-24 2005-04-07 The Regents Of The University And Methods Compositions antimicrobiennes en nanoemulsion et methodes associees
US20060270614A1 (en) * 2005-05-24 2006-11-30 Sekhar Boddupalli Use of chalcones for the treatment of viral disorders
DE202013105715U1 (de) * 2013-08-22 2014-02-19 Sipnose Ltd. Vorrichtung zur Abgabe einer vorbestimmten Menge einer Substanz an eine natürliche Öffnung des Körpers
WO2016014699A1 (fr) * 2014-07-22 2016-01-28 Ralco Nutrition, Inc. Compositions antivirales et procédés

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD2470F1 (en) * 2002-09-06 2004-06-30 Inst Cercetari Stiintifice Process for production of snack canned chick-pea
CN106179143A (zh) * 2016-08-25 2016-12-07 上海应用技术学院 一种薰衣草香精淀粉胶囊及其制备方法
US20190298787A1 (en) * 2018-04-02 2019-10-03 Imam Abdulrahman Bin Faisal University Antimicrobial extracts of boswellia and thyme

Also Published As

Publication number Publication date
AU2021246761A1 (en) 2022-12-08
US20240082336A1 (en) 2024-03-14
US20230173010A1 (en) 2023-06-08
EP4125981A1 (fr) 2023-02-08
EP4125981A4 (fr) 2023-12-27
CA3179222A1 (fr) 2021-10-07
US20240075090A1 (en) 2024-03-07
US11865154B2 (en) 2024-01-09
GB2595427A (en) 2021-11-24
WO2021202823A1 (fr) 2021-10-07

Similar Documents

Publication Publication Date Title
Mestecky et al. Mucosal immunology
Høiby Pandemics: past, present, future: that is like choosing between cholera and plague
King et al. Historical perspective of rabies in Europe and the Mediterranean Basin
Panda et al. Human Diseases
Nava-Frías et al. Chikungunya fever: current status in Mexico
Gajdusek Urgent opportunistic observations: the study of changing, transient and disappearing phenomena of medical interest in disrupted primitive human communities
Sompayrac How pathogenic viruses work
US11865154B2 (en) Therapeutic treatment for the coronavirus disease COVID-19
Ramos et al. The prehistory of mycotoxins: related cases from ancient times to the discovery of aflatoxins
Li et al. A double-blind, randomized, placebo-controlled multicenter study of oseltamivir phosphate for treatment of influenza infection in China
Kupperberg The influenza pandemic of 1918-1919
Upadhyay Climate induced virus generated communicable diseases: management issues and failures
Tadepalli Novel remedial approaches against virulent corona viruses
Mohsina et al. Prevalence, pathogenesis and identification of clinical risk factors associated with dengue virus (DENV)
Newfield Livestock plagues in late antiquity, with a disassembling of the bovine panzootic of AD 376-386
Hollenbeck The 1918-1919 influenza pandemic: a pale horse rides home from war
Goldsmith Influenza: The Next Pandemic?
Basgoz et al. Case 21-1998: a 32-year-old woman with pharyngeal spasms and paresthesias after a dog bite
Ahmed A study on antiarthritic and anti ulcer Activities of saraca indica bark in rats and Mice
Sultana et al. A Narrative Review on Argentine Hemorrhagic Fever: Junin Virus (JUNV)
Uafiznltad Worldwide Report
Usman et al. Investigating Covid-19 and Prophylactive Measures to Contain Spread of the Disease
H Wassili et al. Ghetto Poverty and Pollution in Egypt: A Deadly Threat for Western Countries Caused by New and Infectious Mutants. A Cultural, Social and Microbiological Synopsis
Applin Medical physiology
RALLU What Killed Pacific Islanders: Epidemics or Colonization? The Cases of Tahiti and the Marquesas

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION